Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297009 | 0.87 | CA1 (0.31) | — | |
| SCHEMBL19297003 | 0.86 | CYP1A2 (0.33) | CYP1A2CYP1B1GPR55 | |
| SCHEMBL22031947 | 0.81 | — | — | |
| SCHEMBL8404592 | 0.81 | CYP1A2 (0.38) | CYP1A2CYP1B1 | |
| SCHEMBL12052976 | 0.68 | GPR55 (0.40) | GPR55 | |
| SCHEMBL6127869 | 0.68 | MAPT (0.41) | GPR55 | |
| SCHEMBL8962186 | 0.67 | GPR55 (0.32) | GPR55 | |
| SCHEMBL13532976 | 0.67 | CYP2B6 (0.43) | CYP1A2 | |
| SCHEMBL9422414 | 0.66 | CYP1A2 (0.33) | CYP1A2CYP1B1 | |
| SCHEMBL19814039 | 0.64 | CYP1A2 (0.39) | CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CYP1A2 4048/4885CYP1B1 2470/4885GPR55 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.